|
Delayed
Toronto S.E.
05:49:54 03/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 0.0950 CAD | 0.00% |
|
-5.00% | -5.00% |
| 14/08 | Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 26/06 | Resverlogix Corp. - Shareholder/Analyst Call |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 23.63M | - | - | - | - | - |
| 68.87B | |||||
| 65.29B | |||||
| 27.65B | - | ||||
| 25.77B | |||||
| 26.08B | - |
- Stock Market
- Stocks
- RVX Stock
- Charts Resverlogix Corp.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
